STOCK TITAN
  1. Home
  2. News
  3. SCLX

Scilex Holding Company - SCLX STOCK NEWS

Welcome to our dedicated page for Scilex Holding Company news (Ticker: SCLX), a resource for investors and traders seeking the latest updates and insights on Scilex Holding Company stock.

Scilex Holding Company (NASDAQ: SCLX) is a forward-thinking, revenue-generating firm headquartered in Palo Alto, California, known for its focus on acquiring, developing, and commercializing non-opioid pain management products. The company's mission centers around addressing acute and chronic pain with innovative treatments that offer alternatives to opioid medications.

Scilex's flagship commercial product is ZTlido (lidocaine topical system) 1.8%, a prescription product approved by the U.S. Food and Drug Administration (FDA) for relieving neuropathic pain associated with postherpetic neuralgia, a form of post-shingles nerve pain. Another key product is ELYXYB, an FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.

The company also markets Gloperba (colchicine USP), the first and only liquid oral formulation of colchicine for the prophylaxis of painful gout flares in adults. The FDA recently approved the commercial manufacturing of Gloperba, and it is set to launch in major wholesalers and pharmacies by June 2024.

In addition to their commercial products, Scilex is advancing three promising product candidates:

  • SP-102 (SEMDEXA™): A novel, viscous gel formulation of dexamethasone sodium phosphate for epidural injections to treat lumbosacral radicular pain, including sciatica. It has completed a Phase 3 study and was granted Fast Track status by the FDA in 2017.
  • SP-103: A next-generation, triple-strength formulation of ZTlido for the treatment of chronic neck pain, which completed a Phase 2 trial in low back pain and received Fast Track status from the FDA in 2023.
  • SP-104: A novel, low-dose delayed-release naltrexone hydrochloride capsule for the treatment of fibromyalgia, with Phase 1 trials completed in mid-2022.

Recently, Scilex resolved ANDA patent issues, paving the way for final FDA approval of an expanded label for Gloperba, which aims to provide specific dosing guidance for patients with renal impairment.

Scilex's focus on unmet needs in pain management, combined with its robust pipeline and strategic partnerships, positions it as a leader in the non-opioid pain management market. The company is dedicated to improving patient outcomes and advancing non-opioid alternatives to meet the growing demand for effective pain relief solutions.

For more information, visit www.scilexholding.com.

News

Scilex Holding Company Files Emergency Motion in the United States Bankruptcy Court for the Southern District of Texas for Entry of an Order Compelling the Production of Books and Records from certain Brokers, Dealers, Banks and other Nominees Pursuant to Rule 2004 of the Federal Rules of Bankruptcy Procedure

Rhea-AI Summary
Scilex Holding Company has filed an emergency motion for the production of books and records from certain brokers, dealers, banks, and other nominees. The motion was filed in the U.S. Bankruptcy Court for the Southern District of Texas. Scilex previously provided proposals to Short Sellers and lenders of short positions, offering them the opportunity to cover their positions and avoid further expenses. The Short Seller Proposal ended on October 27, 2023, while the Lender Proposal is still in effect until October 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
acquisition
-
News

Scilex Holding Company Retains Warshaw Burstein, LLP and Christian Attar Law to Investigate Potential Naked Short Selling, Short Positions, Stock Lending Program Activities and Market Manipulation of Its Stock Price

Rhea-AI Summary
Scilex Holding Company retains legal firms to investigate potential market manipulation of its restricted shares of common stock
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.92%
Tags
none
-
News

Scilex Holding Company Provides Notice to All Lenders of Short Positions in the Restricted Dividend Shares of Scilex Holding Company

Rhea-AI Summary
Scilex Holding Company provides notice to lenders of short positions in restricted shares of Scilex common stock. The Scilex Dividend Stock was subject to restrictions on transfer through March 31, 2024. Short sellers who engaged in illegal naked short selling did not opt into a settlement. Scilex now offers a proposal to lenders of short positions to cover their positions and receive a release from Scilex for any claims related to naked short selling. The Lender Proposal commences on October 9, 2023, and ends on October 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.9%
Tags
dividends
News

Scilex Holding Company Provides Notice to All Record Holders and Beneficial Owners of Restricted Shares of Scilex Holding Company

Rhea-AI Summary
Scilex Holding Company provides notice to record holders and beneficial owners of restricted shares of Scilex common stock. Sorrento Therapeutics authorized a dividend of 76,000,000 shares of Scilex common stock to equity holders. Short selling of Scilex common stock may constitute a violation of SEC Regulation SHO. Settlements reached with short sellers resulted in approximately 800,000 short positions closed or covered. Short sellers who engaged in illegal naked short selling have the opportunity to cover their short positions and avoid fees and expenses. Proposal allows short sellers to purchase shares in the open market to close out or cover their short positions. Deadline to participate in the proposal is October 27, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
none
-
News

Scilex Holding Company Submits a Request to the Securities and Exchange Commission to Withdraw its Registration Statement on Form S-1 (File No. 333-271401)

Rhea-AI Summary
Scilex Holding Company has submitted a request to withdraw its Registration Statement on Form S-1, which had not been declared effective by the SEC. No securities had been sold pursuant to the Registration Statement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
none
-
News

Scilex Holding Company announces the State of Indiana Medicaid will add Elyxyb as a preferred agent to its preferred drug list (PDL) effective October 1, 2023

Rhea-AI Summary
Scilex Holding Company announces that Elyxyb will be added to Indiana Medicaid's Preferred Drug List, improving access for approximately 1.2M patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.8%
Tags
none
News

Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company

Rhea-AI Summary
Sorrento Therapeutics completes sale of securities to Scilex Holding Company for $110 million, losing controlling interest over Scilex. Oramed SPA terminated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.71%
Tags
none
-
News

Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.

Rhea-AI Summary
Scilex Holding Company completes purchase of securities from Sorrento Therapeutics, Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.71%
Tags
none
-
News

Scilex Holding Company Announces the Completion of its SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, Phase 2 trial which achieved its objectives to Evaluate the Safety and Efficacy of SP-103 in Subjects with Moderate to Severe Acute Lower Back Pain (LBP)

Rhea-AI Summary
Scilex Holding completes Phase 2 study for SP-103, a potential treatment for acute LBP. No serious adverse events observed. Reduction of pain observed in patients with muscle spasms. Safety outcome confirms expectations. Potential global market opportunity of $10.0 billion by 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
clinical trial
News

Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder

Rhea-AI Summary
Scilex Holding Company announces execution of non-binding term sheets and final order approving the Scilex Term Sheets
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.61%
Tags
none

FAQ

What is the current stock price of Scilex Holding Company (SCLX)?

The current stock price of Scilex Holding Company (SCLX) is $0.4475 as of December 20, 2024.

What is the market cap of Scilex Holding Company (SCLX)?

The market cap of Scilex Holding Company (SCLX) is approximately 72.0M.

What does Scilex Holding Company specialize in?

Scilex specializes in acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain.

What are Scilex's main commercial products?

Scilex's main products include ZTlido (lidocaine topical system), ELYXYB (oral solution for migraines), and Gloperba (liquid colchicine for gout).

What is ZTlido used for?

ZTlido is a prescription lidocaine topical product used to relieve neuropathic pain associated with postherpetic neuralgia.

What is ELYXYB?

ELYXYB is an FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.

What recent approval has Gloperba received?

The FDA recently approved the commercial manufacturing of Gloperba, and it is set to launch in June 2024.

What are Scilex's current product candidates?

Scilex's product candidates include SP-102 (SEMDEXA), SP-103 (triple-strength ZTlido), and SP-104 (low-dose naltrexone hydrochloride).

What is SP-102?

SP-102, or SEMDEXA, is a viscous gel formulation of dexamethasone sodium phosphate for epidural injections to treat lumbosacral radicular pain, such as sciatica.

What is the significance of the FDA Fast Track status for SP-103?

The FDA Fast Track status for SP-103, a triple-strength lidocaine topical product, expedites its development and review process for treating chronic neck pain.

When will Gloperba be available in pharmacies?

Gloperba is expected to be available in major wholesalers and pharmacies starting June 10, 2024.

Where is Scilex Holding Company headquartered?

Scilex Holding Company is headquartered in Palo Alto, California.

Stock SCLX logo
Scilex Holding Company

Nasdaq:SCLX

SCLX Rankings

#4653 Ranked by Market Cap
N/A Ranked by Dividends

SCLX Stock Data

72.01M
128.90M
32.79%
18.16%
4.03%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States of America
PALO ALTO